News & Events
FirstTesta Launches First Blood Genotype Digitisation In Partnership With SCHAF: Aims to Eradicate Sickle Cell Disease in Nigeria
- September 27, 2023
- Posted by: Admin
- Category: News update
Oyo State, Nigeria – September 27, 2023

In a groundbreaking partnership between FirstTesta, Nigeria’s rapidly growing tech-enabled unified diagnostic startup, and the Sickle Cell Hope Alive Foundation (SCHAF), over 250 young individuals undergoing their National Youth Service Corps (NYSC) training in Oyo State were introduced to the life-changing world of Blood Genotype Digitization (BGD). This initiative is set to have a profound impact on over 1,000 communities and 1.5 million people across Nigeria.
FirstTesta’s innovative BGD system is poised to revolutionise healthcare by offering rapid and highly accurate point-of-care diagnostic genotype test, providing results in just about two minutes. Notably, this pioneering technology captures the tested individual’s facial identity alongside the diagnostic test results, digitally storing all details and promptly delivering them to the user’s email.
The event, which took place on September 25, 2023, saw FirstTesta collaborating with SCHAF to educate and empower NYSC members in Oyo State on sickle cell disease awareness.
Sickle cell disease remains a significant public health concern in Nigeria, with a high prevalence rate. Statistics reveal that approximately 150,000 babies are born annually with sickle cell disease in the country, making awareness and accurate genotype testing crucial.
FirstTesta, founded by renowned point-of-care diagnostics expert and public health professional, Akindele Opeyemi, offered free digitised genotype tests valued at 150,000 naira to the participating NYSC members. The impact of this gesture was palpable, as these young individuals expressed their gratitude for the opportunity to have their genotypes accurately determined before considering marriage, a practice that can significantly reduce the incidence of sickle cell disease.
The benefits of Blood Genotype Digitization are manifold and transformative. Key advantages include:
1. Transparency: BGD eliminates the possibility of human error in genotype testing, ensuring transparent and precise results.
2. Accessibility: This technology makes genotype testing more accessible, particularly in remote or underserved areas, where healthcare resources may be limited.
3. Linked to Facial Identity: By connecting genotype data with facial identity, BGD enhances the security and authenticity of medical records.
4. Verifiable Worldwide:Results can be verified from anywhere in the world, offering a level of convenience and accessibility previously unimaginable.
Professor Falusi, the founder of Sickle Cell Hope Alive Foundation, expressed deep appreciation for FirstTesta’s commitment to partnering with SCHAF on the awareness and empowerment project aimed at eradicating sickle cell disease in Nigeria. She also extended her gratitude to Akindele Opeyemi, the founder of FirstTesta, for successfully spearheading the digitization of blood genotypes for these young individuals.
FirstTesta’s smart approach to healthcare, with its Blood Genotype Digitization technology, is poised to transform the lives of millions across Nigeria. As FirstTesta continues to pioneer advancements in healthcare technology, the promise of a healthier, sickle cell-free Nigeria looms ever closer on the horizon.
For partnerships or testing inquiries, interested parties are encouraged to contact FirstTesta via WhatsApp at +2349026812248 or email at firsttestahealthtech@gmail.com